Alpine Immune Sciences Inc
ALPN
ALPN was delisted on the 17th of May, 2024.
63 hedge funds and large institutions have $251M invested in Alpine Immune Sciences Inc in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 33 increasing their positions, 9 reducing their positions, and 15 closing their positions.
700% more call options, than puts
Call options by funds: $8K | Put options by funds: $1K
267% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 9
2% less capital invested
Capital invested by funds: $255M → $251M (-$3.93M)
10% less funds holding
Funds holding: 70 → 63 (-7)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
47% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.25M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.52M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.5M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$1.21M |
| 5 |
CCMU
Cheyne Capital Management (UK)
London,
United Kingdom
|
+$1.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCMIC
Decheng Capital Management III (Cayman)
Grand Cayman,
Cayman Islands
|
-$48.3M |
| 2 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$804K |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$720K |
| 4 |
Walleye Capital
New York
|
-$514K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$508K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Wells Fargo
San Francisco,
California
| – | -$1K | -127 | Closed |
|
77
Nisa Investment Advisors
St. Louis,
Missouri
| – | +$77 | +12 | New |
|
ALPN Hedge Fund Activity: Q4 2022 in Review
63 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Alpine Immune Sciences Inc (ALPN) for Q4 2022, worth a combined $251M — down 1.5% from $255M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of ALPN and 8 opened new positions — a net loss of 7 holders — while 9 trimmed existing stakes and 33 added.
The largest buyer was BlackRock, adding an estimated $3.25M. The largest seller was Decheng Capital Management III (Cayman), exiting entirely with an estimated $48.3M sold.
- 63 institutional investors held Alpine Immune Sciences Inc (ALPN) as of Q4 2022, down from 70 in Q3 2022.
- Funds reported $251M of Alpine Immune Sciences Inc stock for Q4 2022, down 1.5% quarter-over-quarter.
- 8 funds opened new Alpine Immune Sciences Inc positions in Q4 2022 and 15 closed out, a net change of -7 holders.
- The largest Alpine Immune Sciences Inc buyer in Q4 2022 was BlackRock, an estimated $3.25M added.
- The largest Alpine Immune Sciences Inc seller in Q4 2022 was Decheng Capital Management III (Cayman), an estimated $48.3M sold.
Based on aggregated 13F filings for Q4 2022.